#pharmacyeducationcorner
Good afternoon everyone this is sara arakinis your clinical pharmacist welcome to episode number 203 of pharmacies education corner today i’ll be discussing another medication in summary the name of the medication is trilogy ellipta or fluticasone humeclinium and bilanteral inhalation powder this medication is from gsk pharma fda approved announced on september 9
2020 i’ve included a picture of trilogy over here and the elliptic device for you to see and i’ll get into dosing in a second but before that trilogy is a combination of litigation fury and inhaled corticosteroid humeclinium and anticholinergic and voluntarily a long-acting beta-2 adrenergic agonist or laba indicated for the maintenance treatment of patients with
Copd and the maintenance treatment of asthma in patients age 18 years and older the way this medication works and each component works flutiches of urine is a synthetic trifluorinated corticosteroid with anti-inflammatory activity human clinium is a long-acting muscarinic antagonist which is often referred to as an anticholinergic and vilantarol is a long-acting
Beta-adrenergic agonist or um lab as far as dosing goes um it comes in an inhalation powder of two foil blister strips of powder formulation for oral inhalation one strip contains fuzzy kison furate m100 or 200 microgram per ballister and the other contains humichladinum vilantural 62.5 um 25 microgram per blister as far as administration goes it’s for oral
Inhalation and to be used for patients and the maintenance treatment of copd dosing is one actuation of trilogy ellipta of 100-62.5 that’s 25 microgram once daily administered by oral and inhalation as i mentioned maintenance treatment of asthma is one actuation of trilogy elliptic 100 slash 60 2.5 slash 25 microgram or trilogy elliptic sixty two 200 five slash
Twenty five microgram once daily admission by oral inhalation as far as side effects goes uh most common and adverse reactions seen from this medication included respiratory tract infections pneumonia bronchitis oral candidiasis headache back pain arthralgia influenza sinusitis pharyngitis and urinary tract infections and diarrhea and cough and some other side
Effects it’s very important for the pharmacist to know about these side effects and educate the patients especially taking trilogy lip for the first time about the side effects and if they experience any of them to refer back to their pharmacists or clinical specialists for follow-up to 12 weeks then treatment trials of um with uh the mentioned names over here
Were conducted evaluated and the core administration of human clinium plus fulticus and fury slash valentino and the components of trilogy elliptic and compared with placebo plus fully kissing fury and slash cilantro a total of 824 patients uh subjects in the study with copd across two to two 12 weeks randomized double blind clinical trials received at least one
Dose of the umichladinum is 62.5 milli microgame plus publication fury slash will anterior m 100-25 microgram or placebo plus fluticason fury degree ontario 100-25 microgram administered once daily the mean age for these patients was 64 years old in the studies and 92 percent white 66 percent male and m and this was across the all the studies so based on these
Studies and few other ones um trilogy elliptic a combination of fluticasone umiclidinium and bilanterol was approved from gsk pharma on september 9 and 2020 for as a maintenance treatment of patients with copd and maintenance treatment of asthma in patients 18 years and older this is summary information but uh trilogy elliptic um uh for more detailed information
As far as contraindications limitations of use more information about the clean cut trials please refer back to the package insert for trilogy available from gsk farm hope you enjoyed this video as always stay safe and take your medications
Transcribed from video
Trelegy Ellipta – COPD, Asthma- by Saro Arakelians, PharmD- Episode # 203 By Pharmacist Education Corner- by Saro Arakelians
